Pharmacy Automation Market Size, Share & Forecast 2026-2032
Pharmacy automation at $7.64B in 2026 reaching $10.9B by 2032 at 6.10% CAGR. Omnicell alone is 16.5% of the published market and grew just 7% in 2025.
$7.6B
$10.9B
6.1%
Global
Executive Summary
Pharmacy automation is a market whose published figures agree about the present and contradict each other about the future. For 2025 the estimates span just 1.25x, from $7.2 billion to $9.0 billion; for 2032 they span 2.29x, from $7.87 billion to $18 billion - and Meticulous Research's 2032 endpoint of $7.87 billion is 9.3% below IMARC's figure for 2025. The explanation is that Meticulous publishes no base year at all. Back-solving from its own 7.6% rate and its own endpoint gives $4.67 billion for 2025, 35% below IMARC's and 48% below HTF Market Intelligence's. The supply side resolves the growth question rather than the size question. Omnicell, the listed pure-play, reported FY2025 revenue of about $1,185 million - 16.5% of IMARC's whole market - on 7% growth, with fourth-quarter revenue up only 2% and GAAP net income falling from $13 million to $2 million. Adding Becton Dickinson's Medication Management Solutions at roughly $3.5 billion gives two companies an upper bound of 65.1%, although that segment includes Alaris infusion pumps and overstates BD's pharmacy-automation content. The denominators confirm the low end. AHA recorded 6,100 US hospitals from its 2024 survey against 6,093 from 2023, and automated dispensing is already standard in them; an installed base near saturation in a flat denominator grows by replacement, software attach and price. We publish $7.64 billion for 2026 to $10.90 billion by 2032 at 6.10%.
Key Highlights
Published 2025 bases span only 1.25x ($7.2 billion to $9.0 billion) while 2032 endpoints span 2.29x ($7.87 billion to $18 billion), and the lowest 2032 forecast is below the highest house's figure for 2025
Meticulous Research publishes a 7.6% CAGR and a $7.87 billion 2032 endpoint with no base-year value; back-solving gives $4.67 billion for 2025, 35% below IMARC's figure for the same year
Omnicell's $1,185 million for FY2025 is 16.5% of IMARC's whole market - the cleanest ratio in this category, because Omnicell does essentially nothing else
Omnicell grew 7% in 2025 with fourth-quarter growth of 2% and GAAP net income down from $13 million to $2 million, which is not the behaviour of a pure-play in a 12.2% market
IMARC's segment shares against roughly 51,319 derived US retail pharmacies give about $39,100 of annualised automation spend per store per year - an anchor that confirms the published range rather than refuting it
The hospital denominator is flat at 6,100 US hospitals from the 2024 AHA survey against 6,093 from 2023, so hospital dispensing automation grows by replacement and software attach rather than penetration
Market Overview
Market Context
Pharmacy automation is a labour-substitution market dressed as a technology market. The purchase decision in a hospital is driven by DEA recordkeeping, USP 797 and 800 compliance and pharmacist time; the purchase decision in a retail store is driven by prescription volume per labour hour. Neither is a technology adoption curve, and that is why this category behaves unlike the rest of Healthcare IT. Its two denominators are both effectively fixed: AHA counted 6,100 US hospitals in its 2024 survey against 6,093 in 2023, and NCPA counted 18,988 independent pharmacies in 2026 against 18,960 in 2025. The installed base in hospitals is close to universal - a Best in KLAS award category for automated dispensing cabinets exists precisely because every hospital already has them and evaluates them against each other. What is actually changing is where the revenue sits inside a deployment. Omnicell's growth came from connected devices, technical services, SaaS, Expert Services and consumables rather than new placements, and the Swisslog-BD partnership pairs one vendor's robots with another's inventory software. The competitive unit is becoming the workflow, not the machine.
Published sizings of pharmacy automation agree about the present and contradict each other about the future. For 2025 they run $7.2 billion to $9.0 billion, just 1.25x; for 2032 they run $7.87 billion to $18 billion, 2.29x - and Meticulous Research's 2032 forecast of $7.87 billion is 9.3% below IMARC's figure for 2025. Meticulous publishes no base year at all; back-solving from its own rate and endpoint gives $4.67 billion for 2025, a third below the consensus. The supply side settles the growth question. Omnicell, the listed pure-play, reported $1,185 million for 2025 - 16.5% of IMARC's whole market - on 7% growth with fourth-quarter growth of 2% and GAAP net income down from $13 million to $2 million. A 12.2% market whose pure-play grows 7% and whose Q4 grows 2% is not a 12.2% market.
Market Stage
Mature
Adoption Level
Automated dispensing is near-universal in US hospitals; retail and central-fill automation is the remaining penetration opportunity
Key Trends
Market Forecast & Data
Base Year (2026)
$7.6B
Forecast (2032)
$10.9B
CAGR (2026-2032)
6.1%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $7.64B |
| 2027 | $8.11B |
| 2028 | $8.60B |
| 2029 | $9.12B |
| 2030 | $9.67B |
| 2031 | $10.26B |
| 2032 | $10.90B |
We publish 6.10%, which is IMARC's own stated rate, and we prefer it to the publisher's own 2034 endpoint because the two disagree: 7.2 x 1.061^9 = $12.27 billion against a published $12.4 billion, an implied 6.23%. Advancing the 2025 base one year gives 7.2 x 1.061 = $7.64 billion for 2026, and interpolating on the same rate gives 7.64 x 1.061^6 = $10.90 billion for 2032, inside the publisher's series rather than at its endpoint. Choosing the low end of a 6.10% to 12.2% published range is a judgement, and three pieces of evidence support it. The hospital installed base is near-universal in a denominator that moved by seven hospitals between two AHA surveys, so penetration growth is largely exhausted there. The listed pure-play grew 7% in 2025 with fourth-quarter growth of 2% and net income down from $13 million to $2 million, which is incompatible with a market compounding at 12.2%. And the per-store arithmetic, at roughly $39,100 a year at IMARC's figures and $48,900 at HTF's, is already a demanding number for an independent pharmacy that NCPA describes as taking more than 96% of its sales from prescriptions. The upside risk to 6.10% is not hardware; it is the software and service attach rate, which Global Market Insights' 67.6% product share implies is already a third of the market and which Omnicell says is where its growth came from.
Market Dynamics
- Pharmacist labour cost and availability make automation a substitution decision rather than a quality one, which is why the published driver lists across every house in the set name labour-cost reduction first
- Software and service attach rates are rising faster than hardware: Omnicell's 2025 growth came from connected devices and technical service offerings alongside SaaS, Expert Services and consumables, which is the part of the market a hardware-only sizing misses
- Central fill and mail-order dispensing concentrate volume into a small number of high-throughput sites where automation economics are strongest, and the category is published as its own sub-market
- The retail pharmacy denominator is large: roughly 51,300 US retail pharmacies by our division of NCPA's 18,988 independents by its own stated 37% share, which at IMARC's figures implies about $39,100 of annualised spend per store per year
- Replacement cycles sustain demand independently of penetration: a dispensing cabinet or counting robot has a five-to-ten-year service life, so a near-universal installed base generates recurring capital demand
Market Segmentation
By Type
- Automated Medication Dispensing Systems
- Automated Storage and Retrieval Systems
- Automated Packaging and Labeling Systems
- Medication Compounding Systems
- Tabletop Tablet Counters
- Pharmacy Management Software and SaaS
By End User
- Hospital and In-Patient Pharmacies
- Retail Community Pharmacies
- Out-Patient and Clinic Pharmacies
- Central Fill and Mail-Order Facilities
- Long-Term Care Pharmacies
By Application
- Drug Dispensing and Packaging
- Drug Storage
- Inventory Management
- Sterile and Hazardous Compounding
Competitive Landscape
Omnicell
Fort Worth, Texas, United States
Reported FY2025 revenue above the midpoint of guidance on 5 February 2026, with product bookings and annual recurring revenue also above guidance, and attributed growth to connected devices and technical service offerings alongside SaaS, Expert Services and consumables. The deceleration is visible in the same release: fourth-quarter revenue of $314 million was up only 2% year on year, and GAAP net income fell to $2 million, or $0.04 per diluted share, from $13 million and $0.27. Launched the Titan XT next-generation dispensing system, framed as a step toward autonomous medication management.
Becton Dickinson (Pyxis)
Franklin Lakes, New Jersey, United States
BD Pyxis MedStation ES won a 2025 Best in KLAS award for Automated Dispensing Cabinets - an award category that exists only because the product class is mature and competitively evaluated at essentially every US hospital - and BD launched the next-generation BD Pyxis Pro Medication Dispensing platform in fiscal 2025. BD stated it was on track to combine its Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar 2026, which will change its segment reporting and may remove even the aggregated figure.
Swisslog Healthcare
Buchs, Switzerland
Entered a co-marketing agreement with BD announced on 9 December 2024, pairing Swisslog robotics with BD Pyxis Logistics smart medication management software to automate pharmacy inventory management in US hospitals. The structure of that deal - robotics from one vendor, inventory software from another - is the clearest signal in this market that the competitive unit is becoming the workflow rather than the machine.
ScriptPro
Mission, Kansas, United States
Sits in the retail and out-patient segment that IMARC puts at 51.2% of the 2025 market - the part with genuine penetration headroom, since the hospital installed base is close to universal. Sells the counting and vial-filling robot together with the management software, which is the integrated model that the Swisslog-BD partnership is an alternative to.
ARxIUM
Winnipeg, Manitoba, Canada
Concentrated in the central fill and high-volume packaging segment, which is published as its own faster-growing sub-market and which reflects the structural direction of travel: automating a small number of very high throughput sites rather than every retail counter. Its absence from the public record, along with Swisslog's and ScriptPro's, is why two disclosed companies appear to be nearly two-thirds of this market.
Capsa Healthcare
Columbus, Ohio, United States
Operates in the long-term care and acute-care medication storage segment, where the economics are driven by nursing workflow rather than pharmacist labour substitution. Represents the long tail of this market that the published totals must contain but that no disclosed figure can reach, and which is therefore the main source of uncertainty in any concentration estimate.
Recent Developments
Reported fiscal year and fourth quarter 2025 results on 5 February 2026: full-year revenue of about $1,185 million, up 7% or $73 million, above the guidance midpoint, with fourth-quarter revenue of $314 million up just 2% year on year and GAAP net income of $2 million or $0.04 per diluted share, down from $13 million and $0.27 in 2024.
Released the 2026 NCPA Digest on 4 October 2026, counting 18,988 independent community pharmacies - essentially unchanged from 18,960 in 2025 - and describing independents as nearly 37% of all US retail pharmacies, with independent pharmacy a $103 billion market in 2025 of which more than 96% of sales came from prescriptions.
Stated it was on track to combine its Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar 2026, a transaction that will change BD's segment reporting and may remove the only aggregated public figure covering the Pyxis franchise.
Launched Titan XT, a next-generation dispensing system that management framed as a step toward autonomous medication management - a repositioning of the category from hardware replacement toward workflow software.
Launched the next-generation BD Pyxis Pro Medication Dispensing platform in fiscal 2025, and BD Pyxis MedStation ES won a 2025 Best in KLAS award for Automated Dispensing Cabinets.
Announced a co-marketing agreement with BD on 9 December 2024 pairing Swisslog robotic medication management with BD Pyxis Logistics smart medication management software to automate pharmacy inventory management in US hospitals.
Regulatory Landscape
Research Methodology
Primary research
- Comparison of the listed pure-play's disclosed revenue and growth rate against each published market size and CAGR, including quarterly deceleration and net income
- Construction of two countable denominators - US retail pharmacies derived from the NCPA Digest and US hospitals from AHA Fast Facts - and derivation of annualised automation spend per site using one publisher's own disclosed segment shares
Secondary research
- Omnicell, Inc., Fiscal Year and Fourth Quarter 2025 Financial Results, 5 February 2026 - FY2025 revenue approximately $1,185 million (+7%, +$73 million), Q4 revenue $314 million (+2%), GAAP net income $2 million or $0.04 per diluted share against $13 million and $0.27 in 2024; growth attributed to connected devices, technical services, SaaS, Expert Services and consumables; Titan XT launch
- Becton, Dickinson and Company fiscal 2025 annual report - Medication Management Solutions revenue of approximately $3.5 billion (read from a revenue-by-segment chart, not a 10-K segment table); BD Pyxis Pro launch and BD Pyxis MedStation ES 2025 Best in KLAS award for Automated Dispensing Cabinets
- NCPA 2026 Digest, released 4 October 2026 - 18,988 independent community pharmacies, nearly 37% of all US retail pharmacies, independent pharmacy a $103 billion market in 2025; NCPA 2025 Digest, 18,960 as of July 2025 and nearly 36%
- American Hospital Association, Fast Facts on U.S. Hospitals, 2026 edition from the 2024 AHA Annual Survey - 6,100 total US hospitals, 5,121 community hospitals, 1,797 rural; 2025 edition from the 2023 survey, 6,093 and 5,112
- IMARC Group, Pharmacy Automation Market, report SR112026A1864, last updated 9 June 2026 - $7.2 billion (2025) to $12.4 billion (2034) at a stated 6.10% CAGR for 2026-2034; North America 54.4% of 2025, automated medication dispensing systems 24.8%, retail pharmacies 51.2%
- Credence Research, Pharmacy Automation Market - $6,297 million (2024) to approximately $13.38 billion (2032) at 9.88%, with medication dispensing cabinets the largest product share in 2024 at 32.6%
- Global Market Insights, Pharmacy Automation Market, report GMI7439, published November 2023 - $6.4 billion (2022) to $13.6 billion (2032) at 7.9%, with products at 67.6% of the 2022 component market and North America at 48.6%
- Meticulous Research pharmacy automation press release, published 2 July 2024 - $7.87 billion by 2032 at 7.6% for 2025-2032, with no base-year value published
- Swisslog Healthcare and BD co-marketing agreement, announced 9 December 2024, pairing Swisslog robotics with BD Pyxis Logistics software for US hospital pharmacy inventory management
Validation: Three tests were run against disclosed revenue and countable denominators rather than against another forecast. First, Omnicell's disclosed FY2025 revenue of about $1,185 million is 16.5% of IMARC's $7.2 billion whole market for 2025, 13.2% of HTF Market Intelligence's $9.0 billion, and 15.1% of Meticulous Research's 2032 endpoint of $7.87 billion; adding Becton Dickinson's Medication Management Solutions revenue of roughly $3.5 billion gives an upper bound of 65.1% of IMARC's total for two companies, with Swisslog Healthcare, ScriptPro, ARxIUM, Capsa and the central-fill specialists unaccounted for. The 65.1% is explicitly a ceiling and not a measurement, because BD's segment includes Alaris infusion pumps and wider medication-management software and was read from a revenue chart rather than a segment table. Second, using IMARC's own disclosed segment shares - retail pharmacies 51.2% and North America 54.4% - against a denominator of roughly 51,319 US retail pharmacies derived by dividing NCPA's 18,988 independents by its own stated 37% share gives about $39,100 of annualised automation spend per store per year, and the same arithmetic on HTF's $9.0 billion gives about $48,900. A counting and dispensing robot is a six-figure capital item with a five-to-ten-year life, so both figures are in the right order of magnitude, and this anchor confirms rather than refutes the published range. Third, Omnicell's revenue against the 6,100 US hospitals recorded by AHA Fast Facts gives $194,262 per hospital per year, which is an overstatement because Omnicell is global with a large retail and central-fill business, but the direction establishes that hospital dispensing is a near-universal installed base in a flat denominator - 6,100 hospitals from the 2024 survey against 6,093 from the 2023 survey. An installed base near saturation in a flat denominator grows by replacement, software attach and price, which is the structural case for the 6.10% low end over the 12.2% high end, corroborated by Omnicell growing 7% with fourth-quarter growth of 2% and net income falling from $13 million to $2 million. These are plausibility and ratio tests, not market estimates. The US retail pharmacy total is our own division of an NCPA count by an NCPA percentage that moved from nearly 36% to nearly 37% between editions, giving totals between 51,319 and 52,744.
Strategic Takeaways
Meticulous Research does not, and its implied base of $4.67 billion for 2025 is a third below the consensus, which is why its 2032 endpoint sits below another house's present
Use Omnicell's disclosed revenue as the first test on any size claim - $1,185 million for FY2025, or 16.5% of the figure we publish - because it is a pure-play and its ratio is therefore interpretable
a pure-play cannot grow slower than its own market indefinitely
AHA counted 6,100 US hospitals in the 2024 survey against 6,093 in 2023, and automated dispensing is already standard in them
The growth that is left is in software, services and consumables attach, not in new machine placements - which is exactly the component split that publishers disagree about including
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Healthcare ITAI In Lab Automation Market$0.6B · 25% CAGR
- Healthcare ITOncology Information Systems Market$8.5B · 7.84% CAGR
- Healthcare ITHealth Data Interoperability Market$6.5B · 13.4% CAGR
- Healthcare ITGlobal Clinical Decision Support Market$6.3B · 10.4% CAGR
- Healthcare ITHospital-at-Home Market$9.3B · 15.9% CAGR
- Healthcare ITGlobal Digital Therapeutics Market$6.0B · 26.2% CAGR